1303973-22-9 Usage
General Description
4-Aminomethyl-1-Boc-3,3-dimethyl-5-oxo-piperidine, also known as AMMDP, is a chemical compound used in the synthesis of pharmaceuticals and research chemicals. It is an intermediate compound that is commonly utilized in the production of various drugs, including antiviral and antitumor medications. AMMDP is known for its unique structure and reactivity, making it a valuable building block in the field of organic chemistry. Additionally, it has been studied for its potential biological activities and is considered a versatile tool for drug discovery and development. Due to its significance in medicinal and chemical research, AMMDP is a compound of interest in the pharmaceutical industry and academic laboratories.
Check Digit Verification of cas no
The CAS Registry Mumber 1303973-22-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,0,3,9,7 and 3 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1303973-22:
(9*1)+(8*3)+(7*0)+(6*3)+(5*9)+(4*7)+(3*3)+(2*2)+(1*2)=139
139 % 10 = 9
So 1303973-22-9 is a valid CAS Registry Number.
1303973-22-9Relevant articles and documents
TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS
-
, (2018/06/12)
Disclosed are methods for treating NMDA receptor-mediated disorders by administering certain NR2B subunit-selective NMDA (N methyl-D aspartate) antagonists. NMDA receptor-mediated disorders include autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders.
3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS
-
Paragraph 0207, (2016/12/22)
Disclosed are chemical entities of Formula (I), wherein R1 and Z are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).